Comparative Pharmacology
Head-to-head clinical analysis: LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE IN PLASTIC CONTAINER versus XYLOCAINE 5 W GLUCOSE 7 5.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE IN PLASTIC CONTAINER versus XYLOCAINE 5 W GLUCOSE 7 5.
LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE IN PLASTIC CONTAINER vs XYLOCAINE 5% W/ GLUCOSE 7.5%
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lidocaine is an amide-type local anesthetic that stabilizes neuronal membranes by blocking voltage-gated sodium channels, thereby inhibiting the initiation and conduction of nerve impulses. It exhibits antiarrhythmic activity by suppressing automaticity and conduction in cardiac tissues.
Lidocaine is an amide-type local anesthetic that stabilizes the neuronal membrane by inhibiting sodium ion channels, thereby blocking the initiation and conduction of nerve impulses.
Antiarrhythmic: 1-1.5 mg/kg IV bolus, may repeat 0.5-0.75 mg/kg in 5-10 minutes; maximum total 3 mg/kg. Followed by continuous IV infusion 1-4 mg/min. Local anesthesia: maximum 4.5 mg/kg (300 mg) without epinephrine; 7 mg/kg (500 mg) with epinephrine.
Adult: 5-25 mL (250-1250 mg lidocaine) of 5% lidocaine with glucose 7.5% solution, administered by caudal or lumbar epidural injection, single dose. Max total dose: 1250 mg.
None Documented
None Documented
Terminal elimination half-life: 1.5–2 hours (normal cardiac output and hepatic function). Prolonged in heart failure (up to 10 hours), hepatic disease (up to 5–15 hours), and with continuous infusion (due to saturable metabolism).
1.5-2 hours (terminal); prolonged in heart failure, hepatic disease, or elderly; neonates 3-6 hours due to immature hepatic function.
Renal: ~90% as metabolites (including monoethylglycinexylidide [MEGX] and glycinexylidide [GX]) and ~10% unchanged. Biliary/fecal: <3%.
Hepatic metabolism (90% N-dealkylation by CYP1A2/CYP3A4 to monoethylglycinexylidide and glycinexylidide); renal excretion of metabolites and parent drug (<10% unchanged); <1% biliary/fecal.
Category A/B
Category C
Local Anesthetic / Antiarrhythmic (Class Ib)
Local Anesthetic